Gilead Sciences (GILD) News Today → America could fall from this event (From Porter & Company) (Ad) Free Gild Stock Alerts $67.54 +1.58 (+2.40%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 6:51 PM | marketbeat.comPrincipal Financial Group Inc. Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Principal Financial Group Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,459,552 shares of theMay 13 at 5:44 PM | finance.yahoo.comOne stock is dragging down the S&P 500's earnings growthMay 13 at 7:14 AM | marketbeat.comGilead Sciences Q1 Earnings TranscriptMay 13 at 3:34 AM | americanbankingnews.comZacks Research Equities Analysts Reduce Earnings Estimates for Gilead Sciences, Inc. (NASDAQ:GILD)May 12 at 5:50 PM | marketbeat.comQRG Capital Management Inc. Has $32.56 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)QRG Capital Management Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 401,972 shares of the biopharmaceuticMay 11 at 11:47 PM | marketbeat.comDimensional Fund Advisors LP Grows Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Dimensional Fund Advisors LP raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,783,195 shares of the biopharmaceutical compMay 10, 2024 | benzinga.comDecoding Gilead Sciences's Options Activity: What's the Big Picture?May 10, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Private Advisor Group LLCPrivate Advisor Group LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 39.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,510 shares of the biopharmacMay 9, 2024 | businesswire.comArcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | businesswire.comKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | marketbeat.comNational Pension Service Acquires 52,214 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)National Pension Service grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,358,832 shares of the biopharmaceutical company's stock after buying anMay 9, 2024 | forbes.comWill Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75?May 7, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)Charles Schwab Investment Management Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,281,489 shares of the biopharMay 7, 2024 | finance.yahoo.comGilead Helps Put African Nation on Path To Eliminate Hepatitis CMay 7, 2024 | businesswire.comGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024May 6, 2024 | investorplace.comBargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce BackMay 6, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Natixis Advisors L.P.Natixis Advisors L.P. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,620 shares of the biopharmaceutical company's stoMay 5, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lifted by Sheets Smith Wealth ManagementSheets Smith Wealth Management increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 85.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 42,701 shares of the biopharmaceutical company's stock after purchasing an additional 19,64May 5, 2024 | americanbankingnews.comGilead Sciences (NASDAQ:GILD) Sets New 52-Week Low at $64.42May 4, 2024 | marketbeat.comTodd Asset Management LLC Has $974,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Todd Asset Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 95.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,023 shares of the bioMay 4, 2024 | americanbankingnews.comGilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Hold" from BrokeragesMay 3, 2024 | marketbeat.comAmalgamated Bank Sells 19,072 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Amalgamated Bank reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 300,795 shares of the biopharmaceutical company'sMay 3, 2024 | finance.yahoo.comForbes Has Listed Gilead as One of America’s Best Employers for DiversityMay 3, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $64.42Gilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $64.42May 3, 2024 | marketbeat.comMcAdam LLC Has $1.63 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)McAdam LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 132.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,258 shares of the biopharmaceutical company's stMay 1, 2024 | investorplace.comShhh! 3 Secret Biotech Stocks Flying Below Wall Street's RadarMay 1, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Price Target Lowered to $85.00 at Maxim GroupMaxim Group lowered their target price on Gilead Sciences from $90.00 to $85.00 and set a "buy" rating on the stock in a research note on Wednesday.April 30, 2024 | marketbeat.comNorden Group LLC Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Norden Group LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 240.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,163 shares of the biopharmaceutical company's sApril 30, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)April 30, 2024 | markets.businessinsider.comGilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology CatalystsApril 29, 2024 | marketbeat.comRaymond James & Associates Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Raymond James & Associates cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,031,209 shares of the biopharmaceutical company's stApril 29, 2024 | fool.comGilead Sciences: First-Quarter Results Beat EstimatesApril 29, 2024 | markets.businessinsider.comGilead Sciences: Hold Rating with Cautious Outlook Amidst Market Challenges and Growth UncertaintiesApril 29, 2024 | marketbeat.comTraders Purchase Large Volume of Gilead Sciences Call Options (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) saw unusually large options trading on Monday. Traders bought 28,056 call options on the company. This is an increase of 104% compared to the typical daily volume of 13,758 call options.April 29, 2024 | marketbeat.comBarclays Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $76.00Barclays dropped their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an "equal weight" rating on the stock in a report on Monday.April 29, 2024 | seekingalpha.comGilead Sciences, Inc. (GILD) Q1 2024 Earnings Call TranscriptApril 29, 2024 | marketbeat.comPFG Investments LLC Purchases 27,709 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)PFG Investments LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 298.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,988 shares of the biopharmaceutical company's stockApril 27, 2024 | marketbeat.comSector Gamma AS Has $30.98 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Sector Gamma AS reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 382,362 shares of the biopharmaceutical company's sApril 27, 2024 | finance.yahoo.comGilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 27, 2024 | marketbeat.comGilead Sciences, Inc. Declares Quarterly Dividend of $0.77 (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Thursday, April 25th. Investors of record on Friday, June 14th will be paid a dividend of 0.77 per share by the biopharmaceutical company on Thursday, June 27th. This represents a $3.08 annualized dividend and a dividend yield of 4.71%. The ex-dividend date is Friday, June 14th.April 26, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Hold Rating on Gilead Sciences (GILD)April 26, 2024 | marketbeat.comBank Julius Baer & Co. Ltd Zurich Has $34.83 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Bank Julius Baer & Co. Ltd Zurich raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 429,936 shares of the biopharmaceutical company's stock after buying an additional 12,61April 26, 2024 | marketbeat.comMorgan Stanley Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $78.00Morgan Stanley cut their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an "equal weight" rating for the company in a report on Friday.April 26, 2024 | markets.businessinsider.comGilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1April 26, 2024 | finance.yahoo.comGilead Gives Up Big Gains As Covid Drug Drives Its Beat — AgainApril 26, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Receives "Hold" Rating from Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Friday.April 26, 2024 | washingtonpost.comGilead: Q1 Earnings SnapshotApril 26, 2024 | finance.yahoo.comGilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...April 25, 2024 | markets.businessinsider.comDow Inc. Q1 Earnings SummaryApril 25, 2024 | msn.comGilead’s quarterly loss is narrower than expected Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos. Find out more about this $11 AI Coin right now GILD Media Mentions By Week GILD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼0.690.57▲Average Medical News Sentiment GILD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼1716▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SGEN News Today BIIB News Today NBIX News Today TECH News Today QGEN News Today RGEN News Today CRSP News Today DNLI News Today AMGN News Today MRNA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsNo experience to confident trader, meet my student…Wealth Builders InstituteCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOIC Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
